Frank Armstrong, M.D., Named Chief Executive Officer of Bioaccelerate Holdings Inc. NEW YORK, April 18 /PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc. (OTC:BACL.OB) (BULLETIN BOARD: BACL.OB) , an emerging drug development company, announced today the appointment of Frank Armstrong, M.D., to the position of Chief Executive Officer. Dr. Armstrong has previously served as Chief Operating Officer of the Company. Lee Cole, founder, Chairman of the Board and Chief Executive Officer, will remain Chairman. Mr. Cole stated, "As we advance our pipeline of drug candidates through development and commercialization, and continue to make further investments in promising new drug candidates and technologies where we can add significant value, Frank's business acumen, operational capabilities and broad-based experience in the pharmaceutical industry will be even more valuable as we continue to drive near-term licensing and product development opportunities and commercial success." Dr. Armstrong joined Bioaccelerate in January 2005. Prior to Bioaccelerate, he served as Chief Executive Officer of Provensis, a wholly owned subsidiary of BTG plc. Earlier, Dr. Armstrong was Chief Executive Officer of Phoqus, a privately held drug delivery company. Dr. Armstrong has held senior positions at Bayer AG and the Medical Research and Communications Group, Zeneca Pharmaceuticals (now AstraZeneca), based in Germany and the US. "Lee Cole has created a business model for Bioaccelerate that is designed to streamline the development and commercialization of promising drug candidates and rapidly add value for our shareholders, " commented Dr. Armstrong. "Achieving Bioaccelerate's ambitious growth objectives for 2005 and beyond is an extremely exciting challenge and I am looking forward to working with the entire senior management team as well as our partners to drive our success." About Bioacclerate Holdings Inc. Bioaccelerate Holdings Inc. (BACL.OB) is a pharmaceutical development organization ("PDO") that seeks to acquire, develop and commercialize novel pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate uses its broad network of academic, industry and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease and anti-infectives. Bioaccelerate conducts its business directly and through its subsidiaries. The Company holds majority equity interests in 10 biopharmaceutical companies, three of which are public, and holds minority interests in four biopharmaceutical companies, two of which are public. The Company also holds a minority equity interest in a public nanotechnology company. Bioaccelerate's strategy relies on its development network for research, clinical development and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin Board under the symbol "BACL.OB." For more information on Bioaccelerate, visit the Company's website at http://www.bioaccelerate.com/. Bioaccelerate Safe Harbor Statement Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general or Bioaccelerate's compounds under development in particular; the potential failure of Bioaccelerate's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioaccelerate's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioaccelerate's business, structure or projections; the development of competing products; uncertainties related to Bioaccelerate's dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under Bioaccelerate's prior name Mobile Design Concepts, Inc. Bioaccelerate disclaims any obligation to update these forward-looking statements. Contacts: Bioaccelerate Holdings Inc. Christopher O'Toole Senior Vice President 212-332-4387 Matthew Haines (Investors) Vice President Noonan Russo 212-845-4235 Emily Poe (Media) Vice President Noonan Russo 212-845-4266 DATASOURCE: Bioaccelerate Holdings Inc. CONTACT: Christopher O'Toole, Senior Vice President of Bioaccelerate Holdings Inc., +1-212-332-4387; or Investors: Matthew Haines, Vice President, +1-212-845-4235, or Emily Poe, Vice President, +1-212-845-4266, both of Noonan Russo, both for Bioaccelerate Holdings Inc. Web site: http://www.bioaccelerate.com/

Copyright